Contents

Author biography, viii
Preface, x
Acknowledgments, xi

1 First, focusing on “morning hypertension”, 1
What is the “perfect 24-hour blood pressure control”? 1
Definition of “morning hypertension”, 4
How to assess “morning hypertension”, 5
   Home BP monitoring, 7
   Ambulatory BP Monitoring, 9
Feasibility of controlling morning hypertension, 12
Subtypes of morning hypertension, 14

2 Morning surge in blood pressure, 15
Definition of MBPS, 15
Cardiovascular events with MBPS, 16
Organ damage with MBPS, 19
   Hypertensive heart disease, 20
   Vascular disease and inflammation, 21
   Silent cerebrovascular disease, 22
   Chronic kidney disease, 24
Determinants of MBPS, 25
Mechanism of morning risk, 28
Hemostatic abnormality and MBPS, 29
Vascular mechanism of exaggerated MBPS, 31

3 Nocturnal hypertension, 35
Circadian rhythm of BP, 35
Non-dipper/risers of nocturnal BP, 35
Definition and risk of nocturnal hypertension, 38
Mechanism of nocturnal hypertension, 43
Associated conditions 44
   Diabetes, 45
   Chronic kidney disease, 47
Sleep apnea syndrome, 48
Extreme dipper—another type of disrupted circadian BP rhythm, 48

4 What is systemic hemodynamic atherothrombotic syndrome?, 50
A typical case of SHATS, 50
Clinical relevance of SHATS, 52
Pathological target of SHATS, 54
Mechanism of vicious cycle of SHATS, 57

5 Home blood pressure variability, 61
Maximum home SBP, 61
SD of morning SBP, 62
Morning orthostatic hypertension, 64

6 Development of information-technology-based new home blood pressure variability monitoring system, 67
Disaster cardiovascular prevention network, 67
Cutting-edge of HBPM, 71
Basic nocturnal BP monitoring at home (Medinote), 71
“Thermosensitive hypertension” detecting home BP device, 74
Trigger nocturnal BP monitoring, 75
IT-based trigger nocturnal pressure monitoring system, 81
Detection and management of OSAS using new IHOPE-TNP, 82

7 Home blood-pressure-monitoring-guided morning hypertension control, 88
Non-specific treatment, 88
Specific treatment, 89

8 Blood-pressure-lowering characteristics of antihypertensive drugs, 91
Diuretics, 91
Calcium channel blockers, 91
Amlodipine, 92
Nifedipine, 94
Cilnidipine, 95
Azelnidipine, 96
Angiotensin-converting enzyme inhibitors, 96
Angiotensin-receptor blockers, 98
Telmisartan, 98
Candesartan, 98
Olmesartan, 99
Azilsartan, 103
Alpha-adrenergic blockers and beta-adrenergic blockers, 104
RAS inhibitor-based combination, 106

9 Home and ambulatory blood-pressure-profile-based combination strategy, 109
  First-line therapy, 109
  Second-line therapy, 109
    Arterial stiffness type, 109
    Volume retention type, 110
  Third-line therapy, 110

10 Management of resistant hypertension, 111
  Evaluation of resistant hypertension, 111
  Fourth-line therapy, 111
  Circadian medication, 114

11 Era of renal denervation, 115
  Evidence of renal denervation, 115
  Hypothesis of “perfect 24-hour BP control” by renal denervation, 116

12 Latest evidence of controlling morning hypertension: the HONEST study, 118
  Conclusion and perspectives, 122
  References, 123
  Index, 135